The Latest Breaking News from Novo Nordisk

New highly-effective weight loss drugs such as Novo Nordisk's Wegovy are not a “silver bullet” for addressing the rapid rise in global obesity rates, the World Health Organization’s nutrition chief told Reuters, as the agency conducts its first review of obesity management guidelines in more than 20 years.

Drug shortages are growing in the United States, and experts see no clear path to resolving them

A powerful new weight-loss medication may be approved for those aged 12 to 17. But healthcare professionals fear it ignores the underlying socioeconomic causes

Department of Health asks watchdog to assess effectiveness of giving semaglutide to obese youngsters aged 12 to 17

The alert comes after an increased number of social media posts, in which users are marketing the drug as a rapid weight loss solution

GLP-1 agonists are a class of weight loss drug that is going viral on social media — but misinformation is rife

Britain should be taxing unhealthy food and clamping down on marketing, says Sarah Boseley, the Guardian’s former health editor

Suzette Zuena is her own best advertisement for weight loss.

Some doctors, psychologists and eating disorder experts worry these new medications, originally developed to treat diabetes, could become a problem long-term.

Two experts explain.

Critics fear conflict of interest as Novo Nordisk helps medics ‘reduce unnecessary barriers’ to treatment for obesity